Loading…
Concord Drugs (BSE 538965)₹72.72+2.19%Pharmaceuticals
Concord Drugs is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 44.3 against a peer median of 15.9, and ROCE of 5.5% against a peer median of 7.9%, and latest-quarter sales growth of 53.9% against a peer median of 36.0%. By market cap it is #5 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Makers Laboratories | 111 | 14.9 | 9.0 | 3.2 | 0.05 | 0.0 | 141 | 8 | 41.0 | 1,064.4 | vs BSE 538965 |
| Tyche Industries | 109 | 15.9 | 6.8 | 5.0 | 0.00 | 2.8 | 54 | 7 | 31.0 | 22.1 | vs BSE 538965 |
| Pharmaids Pharmaceuticals | 106 | — | −18.4 | −26.5 | 0.49 | 0.0 | 28 | −12 | −38.2 | — | vs BSE 538965 |
| Veerhealth Care | 103 | 177.3 | 7.2 | 3.0 | 0.20 | 0.0 | 33 | 1 | 198.0 | — | vs BSE 538965 |
| Concord Drugs | 96 | 44.3 | 5.5 | 2.6 | 0.28 | 0.0 | 79 | 1 | 53.9 | 900.0 | — |
| Cian Healthcare | 94 | — | −16.1 | −49.2 | 3.38 | 0.0 | 28 | −23 | 41.6 | — | vs BSE 538965 |
| Vaishali Pharma | 91 | 23.4 | 7.9 | 6.0 | 0.28 | 0.0 | 109 | 4 | — | — | vs BSE 538965 |
| Mercury Laboratories | 88 | 21.2 | 12.1 | 9.1 | 0.14 | 0.5 | 76 | 5 | −12.0 | −69.8 | vs BSE 538965 |
| Amwill Health Care | 87 | 7.6 | 21.1 | 15.4 | 0.00 | 1.2 | 43 | 11 | 41.1 | 100.0 | vs BSE 538965 |
| Jfl Life Sciences | 85 | 13.0 | 18.0 | 15.0 | 0.47 | 0.0 | 131 | 6 | −4.2 | 48.6 | vs BSE 538965 |
| Denis Chem Lab | 83 | 10.0 | 14.0 | 9.6 | 0.05 | 2.5 | 182 | 8 | 13.1 | −43.1 | vs BSE 538965 |
| Peer median | 94 | 15.9 | 7.9 | 5.0 | 0.20 | 0.0 | 76 | 5 | 36.0 | 48.6 |
Listed companies closest to Concord Drugs in Pharmaceuticals include Makers Laboratories, Tyche Industries, Pharmaids Pharmaceuticals, Veerhealth Care, Cian Healthcare, Vaishali Pharma, Mercury Laboratories, Amwill Health Care.
Makers Laboratories, with a market cap of ₹111 Cr.
Concord Drugs trades at a P/E of 44.3; the median of its peer set is 15.9. A P/E above or below the median is a description, not a judgement on value.
Concord Drugs' return on capital employed is 5.5%, below the peer median of 7.9%.